



Research Article

NABUMETONE IN BINARY SOLVENTS: SOLUBILITY ANALYSIS

Meena Kharwade ^{*1}, C.V.S. Subrahmanyam ², Pramod Kharwade ³

¹Assistant Professor, Anjuman-I-Islam Kalsekar Technical Campus, New Panvel, Navi Mumbai, India

²Professor & Principal, Dept. of Pharmaceutics, Gokaraju Rangaraju College of Pharmacy, Osmania University, Bachupally, Hyderabad, AP, India

*Corresponding Author Email: meenakharwade@yahoo.com

Article Received on: 02/05/17 Approved for publication: 18/11/17

DOI: 10.7897/2230-8407.0811215

ABSTRACT

The solubility prediction of nabumetone was studied in different solvent system (hexane- ethyl acetate- ethanol- water). The theories such as ideal, Hildebrand-Scatchard and extended Hildebrand solubility approaches were used for finalizing the solubility behavior of nabumetone. Entropy of fusion expression was used to calculate the ideal solubility. The experimental mole fraction solubility deviated from the ideal mole fraction solubility, indicating the self association of solute or solvent or both in solution. The extended Hildebrand equation was used to reproduce solubilities of nabumetone in selected solvent blend. The solubilities of nabumetone were back calculated with an interaction energy term 'W' and rational activity coefficient term ' $(\log_{10} \gamma_2)/A$ '. These parameters were regressed against a polynomial of δ_1 , solubility parameter of solvent blend. Solubility parameter of the nabumetone δ_2 was determined and found to be - 20 MPa^{1/2}.

Key words: Nabumetone, interaction energy term, solubility behavior, extended Hildebrand, solubility parameter.

INTRODUCTION

Solubility parameter, δ , is an intrinsic physicochemical property of a substance, and is expressed as square root of the cohesive energy density. It affords a numerical approximation of the degree of interaction between materials. It has been found particular use in predicting solubility, selection of solvents and cosolvents for increased solubility¹, chemical kinetics², drug action, drug transport kinetics^{3,4}, structure activity relationship⁵, in situ release of theophylline⁶, gas-solid chromatography⁷, selection of excipients for formulations⁸, dosage form technology and design⁹, fast prediction of basic properties of materials¹⁰, solvent selection for organic reactions¹¹, prediction of adhesion of film coating to tablets¹², selection of co-formers for co-crystal formation¹³. Therefore, the specific value of the solubility parameter of a drug is of concern. Various theoretical as well as experimental methods exist to determine the solubility parameter of drug. Current theoretical methods, i.e., group contribution methods Fedors¹⁴, Hoy's and Van Krevelan method¹⁵ and experimental method for δ , are detailed in this paper.

The rationale of present investigation is to test current approaches for estimating the solubility behavior and solubility parameter of nabumetone in the context of existing theories, such as ideal, regular², and irregular solutions¹⁴. Solubility of nabumetone was determined in n-hexane – ethyl acetate – ethanol – water systems to emphasize the solution behavior. Selected drug (nabumetone) belongs to BCS class II, i.e., low solubility and high permeability. Nabumetone has naphthalene as a skeleton structure without any ionizable functional groups. The solubility behavior of naphthalene was analyzed in individual solvents using extended Hansen's approach, three parameter approach¹⁶. It is doable to fortify the concept by

evaluating structural analogue of naphthalene, namely nabumetone. The extended Hildebrand solubility approach [EHS] used in this article is empirical involving statistical analysis of the obtained datum to recognize the solubility behavior and allows the inference of solubility parameter.

MATERIALS AND METHODS

Materials

The nabumetone was as a gift sample kindly supplied by Dr. Reddys Laboratories Ltd., Hyderabad and used as received. The selected binary solvent mixtures were prepared on the volume basis covers wide range of Hildebrand solubility parameter scale i.e. hexane, ethyl acetate, ethanol, water [analytical grade].

Methods

Solubility measurement

The solubility of nabumetone was determined in saturated solutions of varying compositions of mixed solvent blends (hexane-ethyl acetate-ethanol-water system)^{1,17}. An excess of nabumetone was introduced into stoppered flasks containing binary solvent system. Flasks were shaken (number of strokes was 100 ± 2 per minute) in orbital shaking incubator (Kemi Instruments, Kerala, India) at 25 ± 1 °C for 72 hours. Preliminary studies indicated that the time period of 72 hrs is sufficient for saturation at 25 °C. These equilibrated solutions were removed, filtered (using Whatman filter papers of pore size 0.22 μ) to separate the saturated solutions from excess solid drug. The saturated solutions were diluted with 0.01 mol·L⁻¹ hydrochloric acid solution and assayed spectrophotometrically (UV- 1700, Shimadzu, Japan) at maximum wavelength of absorption i.e. 330 nm¹⁸. Nabumetone in 0.01 mol·L⁻¹ hydrochloric acid obeys Beer's law in the range of 20 to 100

µg·ml⁻¹ at 330 nm. The experimental solubility results were recorded as an average of three trials.

Solubility parameter and molar volume of nabumetone

The floatation technique was used to obtain the molar volume of nabumetone experimentally²² and theoretically by Fedors substituent constants method¹⁶. The total solubility parameter (δ₂) of nabumetone was calculated by the group contribution methods like Fedors¹⁴, Hoy's and van Krevelan¹⁵. The solubility parameters of the solvents were taken from the literature^{19,20}.

Differential scanning calorimeter

Differential scanning calorimeter (DSC of 6300, Sicko, Japan) of nabumetone was done to determine the heat of fusion and fusion temperature. The thermal behavior of the drug was studied at heating rate of 5 °C per min under nitrogen atmosphere (flow rate 50-60 ml·min⁻¹). The molar heat of fusion was calculated in 35.16 KJ/mol using the molecular weight of nabumetone (228.29 g/mol) at a fusion temperature of 83.6 °C. This value was measured in triplicate and found certainty in the value. The ideal mole fraction solubility (X₂ⁱ) of crystalline solid in solvent mixtures was calculated from:

$$-\log_{10} X_2^i = \frac{\Delta S_f}{R} \log \frac{T_0}{T} \quad (1)$$

Where, X₂ⁱ is the ideal mole fraction solubility of solute; ΔS_f is the entropy of fusion (kJ·mol⁻¹), is determined using the relationship ΔH_f = T₀ · ΔS_f. T₀ is the melting point of the solid solute; T is the temperature of the solution, (25 °C)^{19,20}.

Statistical analysis

In-house software was developed in BASIC and used for calculating the drug solubility. Mean, standard deviation and regression analysis of the experimental data and the graphs were generated using statistical function of the M.S. Excel program. The graphs were generated using M.S. Excel and the entire text was processed in MS Office.

RESULTS AND DISCUSSION

The melting point T₀ determined by open capillaries (80-85 °C) and DSC fusion temperature (83.6 °C) were closer to the literature value of nabumetone (80 °C)¹⁸. The ideal mole fraction solubility of nabumetone was obtained as 0.131467, based on entropy of fusion (eqa.1)¹⁹. The mole fraction experimental solubilities of nabumetone in different solvents system (hexane-ethyl acetate- ethanol-water) at 25 °C plotted against the solubility parameter of solvent blends are shown in Figure 1.




Figure 1: Solubility profiles of nabumetone against solubility parameter of different solvents system.

As per Figure 1, the experimental solubility curve appears to be an asymmetrical bell-shaped with a peak at 8.9 H. The observed solubilities were lower in most of the solvent blends than the ideal solubilities except in one solvent blend (peak) indicating the self association of drug or solvent (or both) (failure of ideal solution theory).

Solubility Parameter and regular solution

The solubility parameter of nabumetone was computed by Fedors method¹⁴, Hoy's fragmental constants method and Van Krevelene method¹⁵ and recorded along with experimental results in Table 1. The molar volume estimated from Fedors group contribution method and experimentally was 241.8 cm³·mol⁻¹ and 224.465 cm³·mol⁻¹, respectively¹⁶. The nabumetone solubility data were verified from the regular solution theory (Hildebrand-Scatchard equation 2) and the peak

solubility was found to be 18.205 MPa^{1/2} (8.9 H) (where δ₁= δ₂) (Figure 1).

$$-\log_{10} X_2 = -\log_{10} X_2^i + \frac{V_2 \Phi_1^2}{2.303 RT} (\delta_1 - \delta_2)^2 \quad (2)$$

where, volume fraction $\Phi_1 = \frac{V_1 (1 - X_2)}{V_1 (1 - X_2) + V_2 X_2} \quad (3)$

Where, δ₁ and δ₂ are solubility parameters of solvent and solute, respectively, H; V₂ is the molar volume of solute, cm³·mol⁻¹; Φ₁ is the volume fraction of solvent, T is the absolute temperature of the solution (room temperature), °C; R is the Ideal gas constant; X₂ⁱ is the ideal solubility and X₂ is the experimental mole fraction solubility of regular solution.

According to Hildebrand-Scatchard equation, regular solubility is utmost and can be equalize to ideal mole fraction solubility (X_2^i). Consequently, the solubility parameter of solvent (δ_1), can be taken from the graph at the point of peak solubility, which is believed to be equivalent to δ_2 , the drug solubility parameter. The δ_2 value of nabumetone i.e. 8.9 H (18.205 MPa^{1/2}) (from the peak method) did not agree with the values obtained from fragmental constant method (Table 1). Nabumetone has naphthalene as a skeleton structure. The solubility parameter of naphthalene as reported is 9.64 H (19.67 MPa^{1/2}) (group contribution method) and 9.6 H (19.63 MPa^{1/2}) (Extended Hansen approach)^{19,20}. Further, the anthracene has solubility parameter of (20.3 MPa^{1/2}), i.e., 9.92 H. The solubility parameter of nabumetone must be nearer to the values of other

congeners. The addition of methoxy group to naphthalene in nabumetone is expected to decrease the solubility parameter, as similar trends were observed in a number of compounds, i.e., n-propanol and 2-propanol¹⁶. In other words, the solubility parameter of nabumetone expected to be around 9.9 H (20.24 MPa^{1/2}). Considering this, re-verification of solubility analysis is a must. Sometimes the peak solubility fails to provide the δ value of drug²¹, but validity of $X_2 = X_2^i$ is still good in irregular solution²². As shown in Figure 1, the ideal solubility curve crosses the graph at two δ values, i.e., 8.7 H (17.79 MPa^{1/2}) and 9.8 H (20.04 MPa^{1/2}). The δ value of 9.8 H (20.04 MPa^{1/2}) may be a reasonable estimate of solubility parameter, which is nearer to the values obtained by the other methods (Table 1).

Table 1: Solubility parameters of nabumetone from different methods.

Method	Solubility parameter	
	Hildebrand, H	SI units, MPa ^{1/2}
Fedor's ^a	10.17	20.80
Hoy's ^b	9.13	18.67
Van Krevelene method ^c	11.67	23.87
From the graph, at condition $X_2 = X_2^i$	9.8 (and 8.7)	17.79 and 20.04
From first derivative plot	9.8	20.04
Experimental peak solubility in different solvent series	8.9	18.20

^aEstimated from Fedors molar attraction constant [14]

^bEstimated from Hoys substituent method [15]

^cEstimated from Van Krevelan method [15]

Further, accurate results were obtained by plotting a first derivative curve (mean δ Vs $\Delta X_1 / \Delta \delta_1$) and observing the point it crosses the zero value of x-axis. The experimental mole fraction solubility of nabumetone was processed and the plot is drawn (Figure 2). The line crossed the ordinate at about 9.8 H, conforming the solubility parameter of nabumetone as 9.8 H which is also near to the values obtained by other methods (Table 1).




Figure 2: Solubility parameter of nabumetone in different solvents system, first derivative plot

For regular solution behavior, mole fraction solubility was calculated using Hildebrand-Scatchard equation (2) using in-house software. As per Figure 1, solubilities pointed that the experimentally determined mole fraction solubilities were superior to the calculated solubility based on regular solution equation (2) (Figure 1). Therefore, it was assumed that the present data did not satisfy the regular solution theory. The difference in solubilities (poor fit of Hildebran-Schatchard equation) may be due to selection of polar solvents and difference in molar volumes of solute and solvent.

Extended Hildebrand Solubility Approach

The extended Hildebrand solubility approach (EHS) was proposed to understand the irregular behavior of solutions. This approach is partly involve polynomial regression analysis of experimental values, for back calculating the solubility of drugs in polar and nonpolar solvents. Basically, two parameters were evaluated in EHS approach, i.e., 'W' term (interaction energy) or rational activity term ($\log_{10} \gamma_2$)/A values were regressed against the power series, e.g. quadratic, cubic or quartic of the solvent solubility parameter^{23,24}.

Interaction energy term (w)

The 'W' expression was an interaction energy term, which in regular solution theory, was taken to be equal to "geometric mean". Although 'W' presently cannot be estimated based on fundamental physicochemical properties of solute and solvent, 'W' may be obtained from the experimental values using equation (4) for each solvent blend (Table 4). Presently, 'W' was evaluated from the knowledge of other terms obtained experimentally (equations 4 and 5).

$$-\log_{10} X_2 = -\log_{10} X_2^i + A (\delta_1^2 + \delta_2^2 - 2W) \quad (4)$$

$$\text{Where, } A = \frac{V_2 \Phi_1^2}{2.303 RT} \quad (5)$$

The 'W' values of nabumetone solubility in different solvent system was regressed against polynomials (quadratic, cubic and quartic) in δ_1 of the solvents. Based on the 'R²' value and 's' value, the present investigation had chosen quadratic equation (equation 6).

Quadratic equation

$$W = 43.29694 + 0.87437\delta_1 + 0.44014\delta_1^2 \quad (6)$$

$n = 14, \quad s = 1.7828, \quad R^2 = 0.99942$

The equation (6) is not in the standard format, i.e., alternate signs. The distribution of errors is random²³. The calculated 'W' values (using equation 6) were nearer to 'W' experimental values (Table 2). The 'W' calculated values were substituted in equation (4) to back calculate the solubility of nabumetone, X_{2(calc)}. A perusal to Table 2, indicates that the solubility curve does not fit well with experimental values, as a result, the

percent error is high (-447 to +58). The percentage error was high at extreme data points, which was considered reason for a drug exhibiting low solubility. The lack of close agreement between X_{2(calc)} and X_{2(exp)} may be due to peak and shoulder observed in the experimental solubility profile. Such a high error was quite common, when nabumetone was intrinsically low soluble.

Table 2: Mole fraction solubility of nabumetone in different solvent system based on interaction energy term (W), at 25 °C

Ratio	δ ₁ , H	A	W(exp) ^c	W(calc) ^a	X _{2(exp)} ^c	X _{2(calc)} ^b	Percent error ^d
Hexane:Ethyl acetate							
100:0	7.3	0.1328132	70.35	73.1347	0.009421	0.051534	-447.035
50:50	8.1	0.0978795	80.2284	79.2567	0.100457	0.064801	35.4913
20:80	8.58	0.0948487	84.2308	83.2003	0.101245	0.064533	36.25771
10:90	8.74	0.1081572	84.7414	84.5599	0.063129	0.057653	8.670852
Ethyl acetate:Ethanol							
100:0	8.9	0.0811128	87.7141	85.9421	0.135912	0.070078	48.43711
50:50	10.95	0.1029870	106.3136	105.6448	0.059883	0.043588	27.20815
20:80	12.18	0.1333208	116.5491	119.2421	0.004100	0.02142	-422.41
Ethanol:Water							
100:0	13	0.1294593	127.8792	129.0469	0.00826	0.016567	-100.564
90:10	14.04	0.1037445	144.1504	142.3336	0.041156	0.017268	58.04183
80:20	15.08	0.1287724	156.9726	156.5724	0.007854	0.006192	21.15174
70:30	16.12	0.1314518	172.4214	171.7633	0.004632	0.003109	32.87698
60:40	17.16	0.1340144	188.4865	187.9063	0.002018	0.00141	30.13956
30:70	20.28	0.1363810	239.3684	242.048	1.66×10 ⁻⁵	8.93×10 ⁻⁵	-439.73
0:100	23.4	0.1363908	306.0054	304.7586	6.45×10 ⁻⁶	2.95×10 ⁻⁶	54.33757

ΔH_f = 8402.6290 cal/mole, melting point = 80°C (353 K), X₂¹ = 0.131467,

Molar volume (V₂) = 182.9278 cm³/mol, δ₂ = 9.8 H

^a → As per equation (6)

^b → As per equation (4)

^c → Average of three determinations

^d → Percent error is determined as [(X_{2 exp} - X_{2 cal}) / (X_{2 exp})] x 100

Table 3: Solubility of nabumetone in different solvent system based on (log γ₂)/A, at 25°C*

Ratio	δ ₁ , H	A	(Log γ ₂)/A (exp)	(log γ ₂)/A (calc) ^a	X _{2(exp)} ^c	X _{2(calc)} ^b	Percent error ^d
Hexane:ethyl acetate							
100:0	7.3	0.132813	8.617336	4.66644	0.009421	0.03155	-234.847
50:50	8.1	0.097879	1.193281	3.57422	0.100457	0.05874	41.53031
20:80	8.58	0.094849	1.195640	3.15324	0.101245	0.06602	34.79077
10:90	8.74	0.108157	2.944905	3.05020	0.063129	0.0615	2.585019
Ethyl acetate:Ethanol							
100:0	8.9	0.081113	87.71411	85.94208	0.135912	0.07555	44.41081
50:50	10.95	0.102987	106.3136	105.64482	0.059883	0.05934	0.899992
20:80	12.18	0.133321	116.5491	119.24215	0.0041	0.03073	-649.547
Ethanol:Water							
100:0	13	0.129459	9.2817	6.04812	0.00826	0.02166	-162.24
90:10	14.04	0.103745	4.86074	8.09749	0.041156	0.01899	53.85139
80:20	15.08	0.128772	9.50116	10.49839	0.007854	0.00584	25.59491
70:30	16.12	0.131452	11.05172	13.16934	0.004632	0.00244	47.32043
60:40	17.16	0.134014	13.53251	16.02888	0.002018	0.00093	53.72768
30:70	20.28	0.136381	28.58161	24.92443	1.66×10 ⁻⁵	5.2×10 ⁻⁵	-216.35
0:100	23.4	0.136391	31.58911	32.58464	6.45×10 ⁻⁵	4.7×10 ⁻⁵	26.87167

ΔH_f = 8402.6290 cal/mole, melting point = 80°C (353 K),

X₂¹ = 0.131467, Molar volume (V₂) = 182.9278 cm³/mol, δ₂ = 9.8 H

^a → As per equation (7)

^b → As per equation (8)

^c → Average of three determinations

The polynomial expressions are empirical and cannot be expected to reproduce the accurate change in solubility. Variable error is observed for individual solvents namely n-hexane, ethyl acetate, ethanol, and water; these might be due to the differences in the nature of solvents.

Rational activity coefficient

The (log₁₀ γ₂)/A values obtained from experimental solubilities may be regressed directly against δ₁ bypassing 'W' and obviating the need for δ₂ in the calculations. (log₁₀ γ₂)/A values were calculated from the experimental solubility of nabumetone in different solvent system using equation (7) for each solvent blend (Table 3). These values can be regressed against a

polynomial in δ_1 of the solvent blend. Thus $(\log_{10} \gamma_2)/A$ values were calculated for each binary mixture (Table 3)

$$\log_{10} (X_2^i / X_2) = \log_{10} \gamma_2 = A (\delta_1^2 + \delta_2^2 - 2W) \quad (7)$$

The cubic regressed expression was chosen considering the low solubility.

$$(\log_{10} \gamma_2) / A = 43.31162 - 9.54812\delta_1 + 0.67089\delta_1^2 - 0.01207\delta_1^3 \quad (8)$$

$$n = 14, \quad s = 3.5363, \quad R^2 = 0.8965$$

Alternative signs of coefficients are in tune with the standard format. The scatter gram indicated the random distribution of errors. From the regression equation (8), the $(\log_{10} \gamma_2)/A$ values were calculated and recorded in Table 3. The calculated $'(\log_{10} \gamma_2)/A'$ values were nearer to $'(\log_{10} \gamma_2)/A'$ experimental values. The $(\log_{10} \gamma_2)/A$ calculated values were substituted in equation (7) to back calculate the solubility of lornoxicam $X_2(\text{calc})$. A perusal to Table 3, indicates that the solubility curve did not fit well with the experimental solubility (percent error was high ranging from - 649 to + 54), particularly near the peak solubility. Keeping in view of the diverse nature of solvents used in this series, the differences in X_2 values can be understandable. However, the present regression analysis and the results are useful for predicting the solubility of nabumetone and justifiable.

CONCLUSION

Solubility analysis of nabumetone was evaluated in different solvent system to predict solubility behavior and solubility parameter of nabumetone. The solubility parameter of nabumetone from various theoretical methods and experimental method was finalized as $\sim 20 \text{ MPa}^{1/2}$ (9.8 H). When the peak solubility is closer to ideal solubility, solubility parameter of a nonpolar drug molecule can be considered at a point that satisfies the condition $X_2 = X_2^i$ in irregular solutions. The solubility behavior failed to satisfy the ideal solubility and Hildebrand- Scatchard equation (regular solution). Extended Hildebrand approach satisfactorily explains the solubility behavior with the help of polynomial expressions in terms of W and $(\log \gamma_2)/A$. Thus solubility of nabumetone in different solvent system gives irregular solution behavior, which is in tune with the nonpolar chemical structure.

REFERENCES

- Subrahmanyam CVS. Essentials of Physical Pharmacy. 1st ed. New Delhi: Vallabh Prakashan; 2003.
- Martin A, Bustamante P, Chun AHC. Physical Pharmacy, 4th ed. New Delhi: B.I. Waverly Pvt; 1999.
- Roy SD, Flynn GL. Solubility and related physicochemical properties of narcotic analgesics. Pharm Res 1998; 15: 1370-1375.
- Martini LG, Avontuur P, George A, Willson RJ, Crowley PJ. Solubility parameter and oral absorption. Eur J Pharm Biopharm 1999; 48: 259-263.
- Khalil SA, Abdullah OA, Mustafa MA. Absorption of some barbiturates by gambusia fish and its correlation to solubility parameter. Can J Pharm Sci 1976a; 11: 26-30.
- Adjei A, Newburger J, Stavchansky S, Martin A. Membrane solubility parameter and *in situ* release of theophylline. J Pharm Sci 1984; 73: 742-745.
- Phuoc NH, Tan LRP, Munafo A, Ruelle P, Nam-Tran H, Buchmann et al. Determination of partial solubility parameters of lactose by gas-solid chromatography. J Pharm Sci 1986; 75: 68-72.
- Forster A, Hemenstall J, Tucker I, Rades T. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int J Pharm 2001; 226: 147-161.
- Hancock BC, York P, Rowe RC. The use of solubility parameter in pharmaceutical dosage form design. Int J Pharm 1997; 148: 1-21.
- Bustamante P, Selles E. Relationship between solubility parameter and binding of drugs by plasma proteins. J Pharm Sci 1986; 75: 639-643.
- Gani R, Jimenez-Gonzalez C, Constable DJC. Methods for selection of solvents for the promotion of organic reactions. Comput Chem Eng 2005; 29:1661-1676.
- Klar F, Urbenatz NA. Solubility parameters of hypromellose acetate succinate and plasticization in dry coating procedures. Drug Development and Industrial Pharmacy 2016; 42: 1621-1635.
- Mohammad AM, Amjad A, Sitaram P. Hansen solubility parameter as a tool to predict cocrystal formation. Int J Pharm 2011: 63-71.
- Fedors RF. A method of estimating both the solubility parameters and molar and molar volumes of liquids. Polym Eng Sci 1974; 14: 147-154.
- Hoy KC. New values of the solubility parameters from vapour pressure data. J Paint Technol 1970; 41: 76-118.
- Martin A, Wu PL, Adjei A, Beerbower A, Prausnitz JM. Extended Hansen solubility approach: Naphthalene in individual solvents. J Pharm Sci 1981:260-264.
- Rathi PB, Mourya VK. Extended Hildebrand Solubility Approach: Satranidazole in Mixtures of Dioxane and Water. Indian j pharm. sci 2011; 73: 315-319.
- Maffet AC, Osselton MD, Widdop B. Clarks analysis of drugs and poisons. 3rd ed. Mumbai: K.M. Vargese Company; 2004.
- Hildebrand JH, Prausnitz JM, Scott RL. Regular and related solutions. New York: Van Nostrand Reinhold: 1970.
- Sathesh-Babu PR, Thimmasetty J, Subrahmanyam CVS, Manavalan R, Valliappan K. Extended Hansen solubility approach: meloxicam in individual solvents. Pak J Pharm Sci 2007; 20: 311-316.
- Wu PL, Martin A. Extended Hildebrand solubility approach: p- hydroxyl benzoic acid in mixture of dioxane -water. J Pharm Sci 1983; 72: 587-592.
- Subrahmanyam CVS, Sreenivasa R, Venkata Rao, Gundu Rao JP. Irregular solution behaviour of paracetamol in binary solvents. Int J Pharm 1992; 78: 17- 24.
- Subrahmanyam CVS, Ravi Prakash K, Gundu Rao JP. Estimation of the solubility parameter of trimethoprim by current methods. Pharmaceutica Acta Helvetiae 1996; 71: 175- 183.
- Rathi PB, Mourya VK. Solubility prediction of satranidazole in N,N dimethyl formamide -water mixtures using Extended Hildebrand solubility approach. Ind J Pharm Sci 2012; 73: 54-58.

Cite this article as:

Meena Kharwade et al. Nabumetone in binary solvents: Solubility analysis. Int. Res. J. Pharm. 2017;8(11):40-44
<http://dx.doi.org/10.7897/2230-8407.0811215>

Source of support: Nil, Conflict of interest: None Declared

Disclaimer: IRJP is solely owned by Moksha Publishing House - A non-profit publishing house, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IRJP cannot accept any responsibility or liability for the site content and articles published. The views expressed in articles by our contributing authors are not necessarily those of IRJP editor or editorial board members.